Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | WNT1 | P04628 | 5/20 | 0.42 |
| ▸ | GSK3B | P49841 | 5/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.42 |
| ▸ | ESRRG | P62508 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3147565 | 0.93 | KDM4E (0.46) | TLR9TLR8TLR7KDM4EMAPT | |
| SCHEMBL1744088 | 0.89 | PIK3C3 (0.46) | TLR9TLR8TLR7PTPN11RXFP1 | |
| SCHEMBL1742863 | 0.84 | KDM4E (0.46) | KDM4EMAPTKITWNT1GSK3B | |
| SCHEMBL1744440 | 0.83 | TLR9 (0.48) | TLR9TLR8TLR7WNT1GSK3B | |
| SCHEMBL1743029 | 0.83 | KDM4E (0.54) | KDM4EMAPTPANK3RXFP1ALDH1A1 | |
| SCHEMBL1741619 | 0.81 | JAK2 (0.42) | KDM4EMAPTKITWNT1GSK3B | |
| SCHEMBL1742775 | 0.81 | KDM4E (0.46) | KDM4EMAPTKITPTPN11ESRRG | |
| SCHEMBL1742297 | 0.80 | HRH3 (0.50) | TLR9TLR8TLR7KDM4EWNT1 | |
| SCHEMBL1744142 | 0.79 | HTT (0.42) | PTPN11DYRK1AESRRGOGA | |
| SCHEMBL4184608 | 0.78 | GRIN2D (0.57) | KDM4EMAPTWNT1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | claimed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| CN-103110635-A | Histamine H3 receptor antagonist | NOVO NORDISK AS | 2013-05-22 | — | — | CN | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-1380598-A1 | Supported catalyst for olefin polymerization and process for polymerizing olefin by means thereof | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-6569800-B2 | Zirconium, hafnium or titanium metallocene; storage stability and high catalyst activity | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2003-05-27 | — | — | US | disclosed |
| US-20030036606-A1 | Resin composition comprising ethylene-based polymers and process for its production | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2003-02-20 | — | — | US | disclosed |
| US-6455647-B1 | CHLORINE-CONTAINING MAGNESIUM SOLID CARRYING AN ORGANALUMIUM COMPOUND, AND A METALLOCENE, THE SOLID MADE BY HEAT TREATING A MAGNESIUM HALIDE HYDRATE; HIGH CATALYST ACTIVITY; DEASHING STEP SUCH AS CATALYST REMOVAL CAN BE OMITTED | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2002-09-24 | — | — | US | disclosed |
| US-6368995-B1 | REQUIRES NO DEASHING, EFFICIENTLY PRODUCES POLYMERS HAVING EXCELLENT POWDER PROPERTIES; HYDROPOLYSILOXANE COMPOUND, A SILANE COMPOUND, CONDENSATES OF THE SILANE, WITH AN ORGANOMAGNESIUM COMPOUND, AN ALCOHOL, AN ORGANOALUMINUM OXY | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2002-04-09 | — | — | US | disclosed |
| US-20020039963-A1 | Catalyst component for polymerization of olefins, polymerization catalyst and process of polymerization of olefins by using the same | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2002-04-04 | — | — | US | disclosed |
| US-6350831-B1 | CATALYTIC ADDITION POLYMERIZATION WITH TRANSITION METAL CATALYST | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2002-02-26 | — | — | US | disclosed |
| US-6323149-B1 | ALCOHOL OR MERCAPTAN SUBSTITUTED TRANSITION METAL METALLOCENE; ORGANIC ALUMINUM OXY COMPOUND OR CATION GENERATOR; GENERATES NO HYDROGEN HALIDE BY HYDROLYSIS AND EASILY HANDLED, AND HAS A HIGH STORAGE STABILITY | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2001-11-27 | — | — | US | disclosed |
| EP-1035138-A1 | SOLID CATALYSTS FOR THE POLYMERIZATION OF OLEFINS AND PROCESS FOR THE PRODUCTION OF OLEFIN POLYMERS THEREWITH | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2000-09-13 | — | — | EP | disclosed |
| EP-0997480-A1 | CATALYTIC COMPONENTS FOR THE POLYMERIZATION OF OLEFINS, POLYMERIZATION CATALYSTS, AND PROCESS FOR POLYMERIZING OLEFINS BY USING THE SAME | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232078-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | TLR9 1791/4885TLR8 680/4885TLR7 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.